Atwater Malick’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.18M Buy
1,018
+3
+0.3% +$3.54K 0.26% 48
2026
Q2
$1.22M Buy
1,015
+97
+11% +$99.1K 0.27% 47
2026
Q1
$844K Sell
918
-104
-10% -$105K 0.23% 48
2025
Q4
$1.1M Buy
1,022
+4
+0.4% +$3.82K 0.3% 40
2025
Q3
$777K Buy
1,018
+13
+1% +$9.7K 0.23% 45
2025
Q2
$783K Hold
1,005
– – 0.25% 47
2025
Q1
$830K Sell
1,005
-20
-2% -$16.6K 0.28% 42
2024
Q4
$791K Buy
1,025
+133
+15% +$110K 0.27% 42
2024
Q3
$790K Hold
892
– – 0.25% 44
2024
Q2
$808K Hold
892
– – 0.28% 42
2024
Q1
$694K Hold
892
– – 0.24% 44
2023
Q4
$520K Hold
892
– – 0.2% 49
2023
Q3
$479K Hold
892
– – 0.21% 45
2023
Q2
$418K Buy
+892
New +$374K 0.18% 49

Other funds holding LLY

Atwater Malick's LLY Position: Q3 2026 in Review

Atwater Malick increased its Eli Lilly (LLY) stake by 0.3% in Q3 2026, buying an estimated $3.54K and bringing the position to 1,018 shares worth $1.18M. The position accounts for 0.26% of the portfolio, ranked #48.

Atwater Malick first reported a position in LLY in Q2 2023 and has held it in 14 quarters since. The position peaked at $1.22M in Q2 2026. 1,134 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Atwater Malick held 1,018 shares of Eli Lilly worth $1.18M as of Q3 2026.
  • Atwater Malick bought 3 Eli Lilly shares in Q3 2026, an estimated $3.54K.
  • Eli Lilly made up 0.26% of Atwater Malick's portfolio in Q3 2026, its #48 holding.
  • Atwater Malick first reported a position in Eli Lilly in Q2 2023 and has held it in 14 quarters since.
  • Atwater Malick's Eli Lilly position peaked at $1.22M in Q2 2026.
  • 1,134 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Atwater Malick's 13F filing for Q3 2026, filed 15 Oct 2026.